Suvizumab (KD-247) is a humanized monoclonal neutralizing antibody targeting the V3 loop of the HIV-1 envelope glycoprotein gp120. This product specifically binds to the V3 domain of gp120, effectively neutralizing various HIV-1 strains (e.g., MN, SF2, and 89.6) and blocking virus-host cell fusion. Suvizumab reduces viral load and is well-tolerated, serving as an important pharmacological tool for researching HIV prevention, passive immunotherapy, and viral immune escape mechanisms.
CAS Nummer:
[914257-21-9]
Target-Kategorie:
HIV Protease
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
